Please login to the form below

Not currently logged in
Email:
Password:

Biogen appoints executive VP, corporate development

Daniel Karp will also become a member of the executive committee

Daniel KarpBiogen has appointed Daniel Karp as its executive vice president, corporate development effective 11 June.

Karp’s new role will see him lead the newly created corporate development function, which will include corporate and business development and corporate strategy.

He will also become a member of the executive committee and will report directly to chief executive officer Michel Vounatsos, who said: “We are very pleased to welcome Daniel to Biogen as we continue our journey as pioneers in neuroscience.

“Daniel's solid experience from Pfizer combined with his scientific and business education will serve him well in this exciting position as we aim to further build our pipeline and portfolio to tackle unmet needs in neurological diseases.”

Daniel joins Biogen from Pfizer where he most recently was Vice President, Worldwide Business Development and head of business development for R&D.  In that role, he led a global team responsible for early science transactions, partnerships and acquisitions across Pfizer's research portfolio.

He said: “It's a privilege to join Biogen, a true leader in neuroscience," Karp said.  "I'm excited to work with Biogen's innovative and talented team as we work to expand the company's portfolio of therapies for people living with serious neurodegenerative diseases.”

11th June 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics